PCSA stock forecast, quote, news & analysis
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products... Show more
Why Processa Pharmaceuticals (PCSA) Stock Is Up +33.8% in the Last 30 Days
Key Takeaways
- Processa Pharmaceuticals (PCSA) shares rose about 33.8% over the last 30 days, climbing from $1.42 on October 7, 2026, to $1.90 on November 6, 2026.
- The rebound was driven largely by post-merger pipeline momentum, including U.S. FDA clearance of an Investigational New Drug (IND) application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria.
- Despite the recent gain, the stock remains below levels from three months earlier, down roughly 17% from about $2.30 in early August 2026.
- The company completed a merger with Vidya Therapeutics and a roughly $200 million private placement in July 2026, with institutional participation from firms including Bain Capital Life Sciences and RA Capital Management.
- Management has stated that current cash resources are expected to fund operations into the second half of 2029.
- For more detail on valuation and outlook, investors can review the company's Price Targets, Earnings, and Forecast pages.
- Readers can also explore Trending AI Robots for algorithm-driven trading strategies across the broader market.
Processa Pharmaceuticals (PCSA) Company Overview and Market Position
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Vero Beach, Florida. Following its merger with Vidya Therapeutics in July 2026, the combined company's lead development program is VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor being evaluated for chronic spontaneous urticaria, food allergy, and relapsing multiple sclerosis. The company also retains its legacy pipeline, including PCS499, an oral deuterated pentoxifylline analog studied for necrobiosis lipoidica, as well as PCS12852 and PCS11T.
Investors follow PCSA closely because the company is navigating a major transformation: a reverse-merger recapitalization, a substantial private placement, and a planned rebranding to Vidya Therapeutics. Its near-term value proposition rests on clinical execution for VT-7208 and a cash runway that management projects will extend into the second half of 2029.
Processa Pharmaceuticals (PCSA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PCSA advanced from a closing price of $1.42 on October 7, 2026, to $1.90 on November 6, 2026, a gain of approximately 33.8%. The move was not linear: shares traded as low as $1.04 intraday on October 9 before recovering, then firmed further following a late-October pipeline announcement.
The broader quarterly picture is more mixed. From a closing level near $2.30 in early August 2026, the stock declined through September and early October before the recent recovery, leaving it down roughly 17% over the trailing three-month period. In effect, the 30-day rally represents a partial retracement of a longer multi-month pullback rather than new all-time highs.
What Drove PCSA Stock Price in the Last 30 Days
The sharpest catalyst in the period came on October 29, 2026, when Processa announced corporate and pipeline progress following the Vidya Therapeutics acquisition. The company reported that the U.S. FDA had cleared an IND for a Phase 2 study of VT-7208 in chronic spontaneous urticaria, with additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis. The announcement also disclosed a research collaboration with Generian Pharmaceuticals focused on a novel oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist, and management reiterated that current cash is expected to support operations into the second half of 2029.
The rebound also coincided with governance and financing developments. On October 9, the company filed a registration statement covering the resale of up to 306.5 million shares tied to the merger and private placement, and filed preliminary proxy materials. Board changes followed, with Justin Yorke stepping down as chairman and Sheila Gujrathi appointed as non-employee executive chair. These structural milestones, combined with the clinical news, helped shift investor sentiment and supported the stock's recovery from its early-October low.
What Drove PCSA Stock Performance Over the Last Quarter
The quarterly decline reflects the complexity of a reverse-merger and recapitalization. The July 2026 merger with Vidya Therapeutics and the roughly $200 million private placement significantly increased the potential share count, as the Series A preferred stock and assumed options convert into common shares. The October S-3 registration outlining the resale of more than 300 million shares added supply overhang, contributing to pressure on the stock through September and early October.
At the same time, shareholders are being asked to approve a reverse stock split at a ratio of between 1-for-3 and 1-for-9, tied to Nasdaq listing requirements and the planned name change to Vidya Therapeutics. These corporate-structure questions have introduced volatility and made the quarter's price action more about deal mechanics and dilution expectations than about clinical data alone. The late-period FDA IND clearance for VT-7208 provided the fundamental catalyst that began to stabilize the shares.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing and most relevant automated trading bots. Tickeron offers hundreds of AI-driven trading robots that monitor thousands of tickers, but only the strongest and most contextually relevant strategies appear in this featured section. These robots vary widely in strategy, timeframe, and performance metrics, giving traders the flexibility to explore approaches aligned with different risk profiles and holding periods. The page is designed to help users identify algorithmic strategies that are currently resonating with market conditions. Investors interested in systematic, data-driven trading approaches can browse the section to see which bots are generating attention at any given time.
PCSA Stock Forecast Drivers: What Investors Should Watch Next
Several near-term factors will likely shape PCSA's trajectory. First, the company's next quarterly earnings report is a key data point, along with any guidance updates on cash burn and development timelines. Second, the November 30, 2026 special shareholder meeting, where investors will vote on the reverse stock split proposal, is a pivotal event that could influence the share count, Nasdaq listing status, and the planned transition to the Vidya Therapeutics name.
On the clinical front, progress on the Phase 2 program for VT-7208 in chronic spontaneous urticaria, and initiation of additional studies in food allergy and relapsing multiple sclerosis, will be closely watched. The Generian Pharmaceuticals research collaboration represents another potential long-term catalyst. Investors should also monitor regulatory developments, competitive dynamics in the BTK inhibitor and FcRn antagonist spaces, and broader biotech sector sentiment, as these factors can amplify volatility in a clinical-stage, post-merger company.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PCSA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PCSA turned positive on October 12, 2026. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PCSA's RSI Indicator exited the oversold zone, 40 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCSA as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
PCSA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCSA crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in 183 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 50 of 57 cases where PCSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 33 cases where PCSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.725) is normal, around the industry mean (3.498). P/E Ratio (2.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. PCSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology